Salud financiera de hoja de balance de Glenmark Pharmaceuticals
Salud financiera controles de criterios 3/6
Glenmark Pharmaceuticals tiene un patrimonio de accionistas total de ₹97.4B y una deuda total de ₹51.8B, lo que sitúa su ratio deuda-patrimonio en 53.2%. Sus activos y pasivos totales son ₹200.1B y ₹102.7B respectivamente. El BAIT de Glenmark Pharmaceuticals es de ₹11.2B, por lo que su ratio de cobertura de intereses es de 2.5. Tiene efectivo e inversiones a corto plazo que ascienden a ₹11.2B.
Información clave
53.2%
Ratio deuda-patrimonio
₹51.82b
Deuda
| Ratio de cobertura de intereses | 2.5x |
| Efectivo | ₹11.24b |
| Patrimonio | ₹97.36b |
| Total pasivo | ₹102.71b |
| Activos totales | ₹200.06b |
Actualizaciones recientes sobre salud financiera
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Recent updates
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10Increases to Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Might Cool off for now
Sep 17Glenmark Pharmaceuticals' (NSE:GLENMARK) Dividend Will Be ₹2.50
Aug 27Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹112.7B) de GLENMARK superan a sus pasivos a corto plazo (₹58.4B).
Pasivo a largo plazo: Los activos a corto plazo de GLENMARK (₹112.7B) superan a sus pasivos a largo plazo (₹44.3B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de GLENMARK (41.7%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de GLENMARK ha pasado de 75% a 53.2% en los últimos 5 años.
Cobertura de la deuda: La deuda de GLENMARK no está bien cubierta por el flujo de caja operativo (13.9%).
Cobertura de intereses: Los pagos de intereses de la deuda de GLENMARK no están bien cubiertos por el BAIT (2.5x cobertura).